shanghai shen lian biomedical corporation announced that the company's pig pseudorabies live vaccine (strain JS-A1) has been approved by the Ministry of Agriculture and Rural Affairs as a new veterinary drug. The vaccine was jointly developed by shanghai shen lian biomedical corporation, Chengdu Shiji Biopharmaceutical Co., Ltd., and the Shanghai Veterinary Research Institute of the Chinese Academy of Agriculture Sciences for the prevention of pig pseudorabies. The product is based on the variant strain of pig pseudorabies virus (strain JS-2012), with the weakened JS-A1 strain derived from high-temperature passaging in vitro as the production strain, prepared through a microcarrier suspension culture production process to produce vaccine antigens, combined with lyophilization protective agents. This vaccine will demonstrate broad application prospects, enrich the company's variety of animal vaccine products, and enhance the company's core competitiveness. However, before the product can be marketed for sale, it still needs to obtain the product approval number and approval documents, and the company will actively carry out related work.